Sermorelin

What Is Sermorelin?

Sermorelin acetate is a synthetic peptide fragment corresponding to the first 29 amino acids of endogenous growth hormone‑releasing hormone (GHRH). This truncated sequence retains full biological activity, making it a potent stimulator of pituitary growth hormone (GH) secretion. Sermorelin has been studied for its potential in age‑related GH decline, pediatric growth disorders, and investigational regenerative medicine.

Mechanism of Action

Sermorelin binds to GHRH receptors on anterior pituitary somatotrophs, activating adenylate cyclase and cyclic AMP signaling pathways. This receptor engagement stimulates pulsatile GH release, which subsequently elevates circulating insulin‑like growth factor‑1 (IGF‑1). IGF‑1 promotes protein synthesis, tissue repair, and metabolic regulation. Unlike synthetic GHRPs (e.g., GHRP‑2, Ipamorelin), Sermorelin acts through the natural hypothalamic‑pituitary axis, preserving physiological feedback mechanisms and reducing risks of overstimulation.

Research & Clinical Data

Sermorelin has been clinically approved in the past for pediatric growth hormone deficiency but is now primarily used in investigational and compounded contexts. Studies suggest benefits in restoring youthful GH secretion patterns, supporting lean body mass, and enhancing recovery. It has been explored in anti‑aging and wellness medicine, though regulatory approval for these indications has not been established. Reported side effects include injection site reactions, headache, and transient flushing.

Purity & Quality

Pharmaceutical‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: FDA‑approved historically for pediatric GH deficiency; currently investigational in anti‑aging contexts.

Classification & Handling Class: Synthetic GHRH analog | Sequence: 1‑29 amino acids | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Limited approval, investigational use